16 results about "Complete antibody" patented technology

The present invention provides a composite molecule, a nucleic acid, a vector, a host cell, and a pharmaceutical composition, and uses of the composite molecule, the nucleic acid, the vector, the host cell, and the pharmaceutical composition in preparation of drugs for treating cancers. The composite molecule comprises an anti-tumor antibody domain, a linker, and pro-IL-15; the anti-tumor antibody domain is linked to the pro-IL-15 by means of the linker; the anti-tumor antibody domain is a complete antibody against an immune checkpoint molecule, a tumor antigen molecule or an immune activation molecule, or a nano antibody or an antigen binding fragment thereof; the linker is a polypeptide linker or a non-peptide linker; the pro-IL-15 is a fusion protein comprising IL-15, an IL-15Rα sushi domain, and a linker peptide, and optionally comprising an IL-15Rβ extracellular domain; and the IL-15Rβ extracellular domain, the IL-15, and the IL-15Rα sushi domain are linked by means of the linker peptide.

Antibodies can treat neurodegenerative disorders (NDs) caused by misfolded proteins. Still, the blood-brain-barrier (BBB) resists their entry, a barrier that can be reduced by scFv instead of whole antibody and conjugating it with transferrin protein to induce transcytosis. While the scFv binds variable heavy and light chains with a non-cleavable linker, a cleavable linker between the scFv and transferrin protein can reduce exocytosis, enhancing the activity of the scFv.

The invention discloses an engineered exosome for expressing a complete antibody and a preparation method of the engineered exosome, and belongs to the field of biotechnology and drug delivery. Aiming at the problem that a complete antibody is difficult to efficiently and stably express on the surface of an exosome membrane in the prior art, the engineering exosome with the complete antibody displayed on the surface is extracted from a culture supernatant after a target antibody and a natural antibody membrane-bound transmembrane region (TMD) sequence are fused, a recombinant lentiviral expression vector is constructed and a host cell is transfected. According to the method, TMD is used as an anchoring element, accurate positioning and efficient expression of an antibody on an exosome membrane are achieved, and the targeting recognition capacity of the exosome and the application potential of the exosome in the fields of targeting delivery, disease treatment and the like are remarkably improved. Experimental results show that the obtained exosome is typical in form, uniform in particle size and high in antibody expression efficiency, and a new technical scheme is provided for a targeting vector system based on the exosome.

Antibodies can treat neurodegenerative disorders (NDs) caused by misfolded proteins. Still, the blood-brain-barrier (BBB) resists their entry, a barrier that can be reduced by scFv instead of whole antibody and conjugating it with transferrin protein to induce transcytosis. While the scFv binds variable heavy and light chains with a non-cleavable linker, a cleavable linker between the scFv and transferrin protein can reduce exocytosis, enhancing the activity of the scFv.

Antibodies can treat neurodegenerative disorders (NDs) caused by misfolded proteins. Still, the blood-brain-barrier (BBB) resists their entry, a barrier that can be reduced by scFv instead of whole antibody and conjugating it with transferrin protein to induce transcytosis. While the scFv binds variable heavy and light chains with a non-cleavable linker, a cleavable linker between the scFv and transferrin protein can reduce exocytosis, enhancing the activity of the scFv.

Antibodies can treat neurodegenerative disorders (NDs) caused by misfolded proteins. Still, the blood-brain-barrier (BBB) resists their entry, a barrier that can be reduced by scFv instead of whole antibody and conjugating it with transferrin protein to induce transcytosis. While the scFv binds variable heavy and light chains with a non-cleavable linker, a cleavable linker between the scFv and transferrin protein can reduce exocytosis, enhancing the activity of the scFv.

The present disclosure provides a method for determining the presence or quantity of antibody fragments in a sample by capturing said fragments on a line or zone comprising immobilized antibodies or binders specific to the antibody fragments The method may further comprise detecting whole antibody on a line comprising immobilized binders specific to the whole antibody. The immobilized binders specific to the antibody fragments may be immobilized on a test line of a test strip, and the immobilized binders specific to the whole antibodies may be immobilized on a control line of the test strip. The capturing of the antibody fragments results in generation of a first result, and the binding of the whole antibody results in generation of a second result. The method may determine total antibody concentration by aggregating measurements of antibody fragments and intact antibodies.

The invention provides methods for producing crystalline an anti-PD-1 monoclonal antibody (mAb), wherein the mAb is pembrolizumab or a pembrolizumab variant, comprising (1) mixing a solution comprising (a) the mAb, (b) polyethylene glycol (PEG), and (c) an additive selected from the group consisting of: caffeine, theophylline, 2′ deoxyguanosine-5′-monophosphate, a bioactive gibberellin, and a pharmaceutically acceptable salt of said bioactive gibberellin, to form a crystallization solution, (2) incubating the crystallization solution for a period of time sufficient for crystal formation; and (3) optionally harvesting the crystalline anti-PD-1 mAb from the solution. In specific embodiments, the PEG is PEG 3350 and the additive is caffeine. The invention also relates to the novel anti-human PD-1 mAb crystals produced by the methods described herein. Characterization of re-dissolved crystalline suspensions using several biochemical methods showed the bio-physical properties of the re-dissolved mAb crystals were consistent with the intact antibody starting sample. The crystals and methods of the invention are amenable to multiple pharmaceutical applications such as purification, storage, formulation, and drug delivery.

The present disclosure relates to methods for selectively reducing CysL97 in a preparation of IL-17 antibodies or antigen binding fragments thereof (e.g., a preparation of secukinumab antibodies) that have been recombinantly produced by mammalian cells. Also provided are purified preparations of IL-17 antibodies or antigen binding fragments thereof produced by such methods, e.g, purified preparations of secukinumab, wherein the level of intact IL-17 antibodies or antigen binding fragments thereof (e.g., secukinumab) in the preparation is high, e.g., at least about 90%, as measured by sodium dodecyl sulfate capillary electrophoresis (CE-SDS), and wherein the level of activity of IL-17 antibodies or antigen binding fragments thereof (e.g., secukinumab) in the preparation is high, e.g., at least about 92%, as measured by cation exchange chromatograph (CEX).

The invention belongs to the technical field of biological medicines, and particularly relates to a human and mouse serum albumin cross reaction nano antibody derived from a fully synthetic antibody library. Nine nano antibodies capable of being specifically combined with human serum albumin are found through nano antibody synthesis library phage screening. A cross-reactive ELISA experiment is carried out on the related nano antibody clones, the four antibody clones are found to have specific binding to MSA, and Nb-HSA-5 shows relatively strong binding force to MSA; the Nb-HSA-4 does not react with the MSA and the BSA at all under the condition that the Nb-HSA-4 is strongly combined with the HSA, so that the combination of the Nb-HSA-4 and the HSA has strong specificity. The anti-HSA nano antibody can be used for preparing an HSA diagnostic kit, a targeted therapeutic drug, a carrier conjugate for prolonging the plasma half-life period of the drug and the like, and a new tool is provided for diagnosis and treatment of various related diseases.

Antibodies can treat neurodegenerative disorders (NDs) caused by misfolded proteins. Still, the blood-brain-barrier (BBB) resists their entry, a barrier that can be reduced by scFv instead of whole antibody and conjugating it with transferrin protein to induce transcytosis. While the scFv binds variable heavy and light chains with a non-cleavable linker, a cleavable linker between the scFv and transferrin protein can reduce exocytosis, enhancing the activity of the scFv.

Antibodies are major effectors of the adaptive immune system. They bind to the unique characteristics of specific molecules (referred to as antigens) provide numerous tools and strategies for diagnostic, research and clinical applications. The ability to sequence several antibodies in a polyclonal mixture, or at least several major forms thereof (or subpopulations with specific binding characteristics), may result in a faster recombinant antibody production process. So far, due to the complexity of the task, there are few attempts to carry out sequencing on the polyclonal antibody. The present application relates to methods of combinatorially assembling several intact antibody chains using methods including crosslinking, intact chain separation, from middle to bottom proteomics and / or assembling a database using combinatorial chains with a proteomic search engine (based on separation, biochemistry and bioinformatics). The methods may also include recombinantly expressing the identified candidate antibodies to test their binding to the target antigen.

The invention relates to the field of artificial intelligence, and particularly discloses an antibody variable region structure prediction method based on structure prior evaluation, which comprises the following steps: S1, screening a high-resolution and high-integrity compound containing a complete antigen and an antibody H / L chain from PDB, and extracting atomic coordinates after processing; s2, calculating geometrical characteristics of a molecular structure and relative spherical polar coordinates of adjacent residues; s3, calculating a structure quality evaluation score according to physical prior and a dihedral angle-atomic spacing mapping formula; s4, screening training data according to scores, and removing low-quality data; s5, constructing an antigen-antibody attribute isomeric graph and initializing a compound graph; s6, embedding related data as enhanced features when the model is initialized; s7, loading an RA-EGN encoder to output a CDR sequence and a 3D coordinate, and splicing a complete antibody structure; and S8, introducing a structure prior loss function fine tuning model, and performing multi-index screening on an optimal result. According to the invention, the problems of low prediction precision and insufficient structure prior utilization of the existing antibody CDR region are solved, and the prediction accuracy of the antibody variable region is improved.

The invention relates to an antibody coupling drug based on a biological orthogonal reaction as well as a preparation method and application thereof, and belongs to the technical field of antibody coupling drugs. In order to solve the problems of low targeting efficiency, limited treatment time window and high system toxicity of the existing ADC drug in the bladder perfusion administration process, the invention provides an antibody coupling drug based on biological orthogonal reaction, the antibody coupling drug comprises a molecule A and a molecule B which are administered step by step, the molecule A comprises a monoclonal antibody and a TCO group which are covalently linked, and the molecule B comprises a monoclonal antibody and a TCO group which are covalently linked; and the molecule B comprises tetraazine-PEG8-K and a cleavable linker GGFG polypeptide-toxic molecule which are covalently linked. According to the step-by-step antibody-coupled drug disclosed by the invention, a complete antibody-coupled drug assembly is formed in a tumor in situ by fully utilizing the tumor targeting characteristic of the A molecules and a rapid biological orthogonal reaction between the A molecules and the B molecules, so that the time limitation of bladder perfusion is effectively overcome, local efficient delivery and safe medication of the tumor are realized, and the treatment effect of bladder cancer is remarkably improved.

Antibodies can treat neurodegenerative disorders (NDs) caused by misfolded proteins. Still, the blood-brain-barrier (BBB) resists their entry, a barrier that can be reduced by scFv instead of whole antibody and conjugating it with transferrin protein to induce transcytosis. While the scFv binds variable heavy and light chains with a non-cleavable linker, a cleavable linker between the scFv and transferrin protein can reduce exocytosis, enhancing the activity of the scFv.

The present disclosure relates to methods for selectively reducing CysL97 in a preparation of IL- 17 antibodies or antigen binding fragments thereof ( e.g., a preparation of secukinumab antibodies) that have been recombinantly produced by mammalian cells. Also provided are purified preparations of IL- 17 antibodies or antigen binding fragments thereof produced by such methods, e.g, purified preparations of secukinumab, wherein the level of intact IL-17 antibodies or antigen binding fragments thereof (e.g., secukinumab) in the preparation is high, e.g., at least about 90%, as measured by sodium dodecyl sulfate capillary electrophoresis (CE-SDS), and wherein the level of activity of IL-17 antibodies or antigen binding fragments thereof (e.g., secukinumab) in the preparation is high, e.g., at least about 92%, as measured by cation exchange chromatograph (CEX).